Steroids and Man Boobs: Causes and Treatment

Steroids and man boobs are closely linked, with certain types of steroid capable of triggering gynaecomastia, the medical term for enlarged breast tissue in men. Whether caused by anabolic-androgenic steroids misused for bodybuilding or by prescribed medicines such as corticosteroids or spironolactone, the underlying mechanism typically involves a disruption to the balance between oestrogen and testosterone. Understanding which steroids carry the greatest risk, how to recognise early signs, and when to seek medical advice is essential for anyone affected by or concerned about this condition.

Can steroids cause man boobs?

Yes, certain steroids can cause gynaecomastia by disrupting the oestrogen-to-testosterone balance, stimulating glandular breast tissue growth beneath one or both nipples.

Yes, certain types of steroid can cause gynaecomastia, the medical term for the development of enlarged breast tissue in men, commonly referred to as man boobs. The mechanism depends on the type of steroid involved, but a common pathway is a disruption to the balance between oestrogen and testosterone in the body. When this balance shifts in favour of oestrogen, glandular breast tissue can proliferate, producing a firm, sometimes tender swelling beneath one or both nipples.

Anabolic-androgenic steroids (AAS), which are sometimes misused for bodybuilding or athletic performance, are among the most frequently implicated. These synthetic compounds can be converted in the body to oestrogen through a process called aromatisation, raising circulating oestrogen levels and stimulating breast tissue growth.^[1][2]

Corticosteroids, such as prednisolone, are prescribed for inflammatory and autoimmune conditions. Their association with true gynaecomastia (involving actual glandular tissue) is less well established than that of AAS. Corticosteroids more commonly cause fat redistribution, including in the chest area, which can produce an appearance similar to gynaecomastia but without glandular involvement. This is known as pseudogynaecomastia. At high doses or with prolonged use, corticosteroids may also suppress the hypothalamic-pituitary-gonadal axis, reducing testosterone production and potentially contributing to true glandular changes, though this is less common.^[6]

It is important to distinguish between true gynaecomastia, which involves actual glandular tissue, and pseudogynaecomastia, which is caused by fat deposition in the chest area without glandular involvement. Both can occur in people who use steroids, but they have different clinical implications and management approaches. A healthcare professional can usually differentiate between the two through clinical examination, and further investigation may be arranged if there is any diagnostic uncertainty. NICE CKS and the NHS website both provide patient-facing guidance on gynaecomastia assessment.

Which steroids are most likely to cause breast tissue growth?

Testosterone-based anabolic steroids and methandrostenolone carry the highest risk due to rapid aromatisation to oestradiol; spironolactone causes gynaecomastia via anti-androgenic effects.

Anabolic-androgenic steroids with a high rate of aromatisation are the most likely to cause true gynaecomastia. Testosterone-based compounds and methandrostenolone (commonly known as Dianabol) convert readily to oestradiol via the aromatase enzyme, and the resulting rise in oestrogen relative to androgen activity is a primary driver of glandular breast tissue development.^[7] Nandrolone has a relatively low rate of aromatisation compared with testosterone; its association with gynaecomastia is thought to relate more to progestogenic activity at breast tissue receptors, though the evidence base for this mechanism is limited and the clinical picture is not fully established.^[9]

Compounds such as trenbolone and stanozolol do not aromatise significantly. Trenbolone has progestogenic properties that may contribute to breast tissue changes in some individuals. Stanozolol is not considered progestogenic, and any association with gynaecomastia is less clearly characterised; it may relate to suppression of endogenous testosterone production rather than direct oestrogenic or progestogenic activity. These mechanistic distinctions are based on limited clinical evidence, and individual responses can vary.

Among prescribed medicines, spironolactone, a steroid-based diuretic used in heart failure and other conditions, is well recognised as a cause of gynaecomastia because of its anti-androgenic properties; this is listed as a dose-related adverse effect in the BNF.^[4] Corticosteroids such as prednisolone and dexamethasone are more commonly associated with fat redistribution and pseudogynaecomastia than with true glandular gynaecomastia, as noted in the section above. Where true gynaecomastia does occur with corticosteroids, it is thought to reflect axis suppression and reduced testosterone production rather than direct oestrogenic stimulation.

It is worth noting that anabolic steroids obtained outside of medical supervision may be unlicensed, falsified, or of unknown purity and dosing. Their use for non-medical purposes is associated with a wide range of serious health consequences beyond gynaecomastia, and anyone experiencing side effects from such substances should seek medical advice without delay. A GP can assess the situation without judgement and arrange appropriate investigation or referral. Further information on the risks of anabolic steroid misuse is available on the NHS website.

What are the signs to watch for and when should you see a doctor?

A firm, disc-like lump beneath one or both nipples is the earliest sign; see your GP promptly, as NICE NG12 recommends a 2-week cancer pathway referral for unexplained breast lumps in men aged 30 and over.

The earliest sign of steroid-related gynaecomastia is typically a small, firm, disc-like lump of tissue directly beneath one or both nipples, which may be tender or sensitive to touch. This is distinct from the softer, more diffuse chest enlargement associated with excess body fat. As the condition progresses, the breast tissue may increase in size and the overlying skin can become stretched.

You should see your GP promptly if you notice any new lump or swelling in the chest area, particularly if it is firm or persistent. NICE guidance (NG12: Suspected cancer: recognition and referral) recommends that men aged 30 and over with an unexplained breast lump should be referred on a 2-week suspected cancer pathway.^[5] Men aged 50 and over with nipple discharge, nipple retraction or other concerning breast changes should also be considered for urgent referral.^[5] While steroid-related gynaecomastia is usually benign, it is important to rule out other causes of breast tissue changes, including rare but serious conditions such as male breast cancer.

Additional features that warrant prompt medical assessment include a hard or fixed mass, skin dimpling, nipple inversion, bloody nipple discharge, swollen lymph nodes in the armpit, or any systemic symptoms such as unexplained weight loss. Nipple discharge in men is uncommon and should always be assessed clinically without delay; it is not a typical feature of gynaecomastia and should not be assumed to be benign.

If you are taking a prescribed steroid and develop breast changes, do not stop the medication without speaking to your prescriber first, as abrupt withdrawal of corticosteroids in particular can be dangerous. Contact your GP to discuss the symptoms and explore whether a dose adjustment or alternative treatment might be appropriate. If any symptom feels severe or rapidly worsening, contact NHS 111 for urgent advice, or call 999 if you believe you are in immediate danger.

How is steroid-related gynaecomastia treated on the NHS?

Treatment begins by removing the causative steroid; persistent cases may be managed with off-label tamoxifen or, where clinically justified, surgical mastectomy subject to local ICB funding criteria.

Treatment of steroid-related gynaecomastia on the NHS depends on the underlying cause, the duration of the condition, and its impact on the individual's physical and psychological wellbeing. The first step is usually to address the causative factor: if the gynaecomastia is linked to anabolic steroid misuse, stopping the offending substance is the primary intervention. Breast tissue may regress over several months once hormonal balance is restored, though regression is more likely in early or recent-onset cases and less predictable in long-standing gynaecomastia. If a prescribed medicine is responsible, the prescribing clinician will weigh the risks and benefits of continuing, reducing the dose, or switching to an alternative.

For persistent or established gynaecomastia that does not resolve after the causative agent is removed, medical treatment may be considered. Selective oestrogen receptor modulators such as tamoxifen are sometimes used off-label in this context; evidence suggests benefit is greatest in early, tender gynaecomastia rather than in long-standing fibrotic cases.^[1] Their use is guided by specialist assessment rather than routine prescribing. NICE CKS guidance on gynaecomastia provides a framework for primary care management and referral decisions.

Surgical treatment, typically subcutaneous mastectomy or liposuction depending on the tissue composition, is available on the NHS in some circumstances, particularly where the condition causes significant psychological distress or functional difficulty.^[1][3] Surgery is generally considered only after medical and causative factors have been addressed. Access to surgery varies between Integrated Care Boards (ICBs), and many ICBs classify gynaecomastia surgery as a procedure of low clinical priority, meaning it may not be routinely funded.^[3] Individual Funding Request (IFR) processes may apply where routine commissioning does not cover the procedure. A GP referral to a breast or plastic surgery clinic is the appropriate route to explore surgical options, and the clinical team will advise on local commissioning criteria.

Can you prevent man boobs if you need steroid treatment?

Using the lowest effective corticosteroid dose for the shortest period reduces risk; for anabolic steroid misuse, stopping entirely is the only safe preventive measure.

Reducing the risk of gynaecomastia during steroid treatment is possible in some cases, though it depends heavily on the type of steroid, the dose, and the duration of use. For people taking prescribed corticosteroids, using the lowest effective dose for the shortest necessary period is the standard clinical approach recommended by NICE and reflected in NHS prescribing guidance.^[6] Regular review with your prescribing clinician allows for dose adjustments as your condition improves, which may reduce cumulative hormonal exposure.

For those using anabolic steroids outside of medical supervision, the most effective preventive measure is to stop use entirely, as there is no safe or medically endorsed way to use these substances for non-therapeutic purposes. Some individuals misusing anabolic steroids attempt to use aromatase inhibitors or selective oestrogen receptor modulators to counteract oestrogenic effects, but these approaches are not supported by robust clinical evidence as a safe preventive strategy, carry their own risks of hormonal disruption, and are not authorised by the MHRA for this purpose. Use without medical oversight is not recommended.

For people receiving prescribed steroid therapy who are concerned about breast changes, open communication with their GP or specialist is the most important step. Monitoring for early signs, maintaining a healthy body weight (which reduces peripheral aromatisation of androgens to oestrogen), and attending regular medication reviews all contribute to minimising risk. Online weight-management consultations are available through services such as Bolt Pharmacy, a GPhC-registered UK online pharmacy, where prescriber review and pharmacist support may help address weight-related factors that can compound hormonal imbalances. Any suspected side effects from prescribed medicines can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions